title: Effects of meloxicam and phenylbutazone on renal responses to furosemide, dobutamine, and exercise in horses.
abstract: OBJECTIVE
  To compare the effects of 2 NSAIDs (phenylbutazone and meloxicam) on renal function in horses.
  
  
  METHODS
  9 Thoroughbred or Standardbred mares (mean ± SD age, 5.22 ± 1.09 years [range, 2 to 12 years]; mean body weight, 470 ± 25 kg [range, 442 to 510 kg]).
  
  
  METHODS
  A randomized blinded placebo-controlled crossover study was conducted to examine the effects of treatment with phenylbutazone, meloxicam, or a placebo (control solution) on renal responses to the administration of furosemide, dobutamine, and exercise (15 minutes at 60% of maximum heart rate). Renal function was assessed by use of bilateral ureteral catheterization for simultaneous determination of creatinine clearance, sodium excretion, and urine flow rate.
  
  
  RESULTS
  Both phenylbutazone and meloxicam attenuated diuresis and natriuresis and reduced glomerular filtration rate, compared with results for the control solution, when horses were treated with furosemide. Mean arterial blood pressure, urine flow rate, and glomerular filtration rate were increased during or after (or both) dobutamine infusion. Both NSAIDs reduced urine flow rate and sodium excretion associated with dobutamine infusion and exercise but had no effect on glomerular filtration rate.
  
  
  CONCLUSIONS
  Responses to meloxicam, a cyclooxygenase (COX)-2 preferential agent, appeared comparable to those detected after phenylbutazone treatment, which suggested that COX-2 was the mediator of prostanoid-induced changes to renal function in horses and indicated that COX-2-preferential agents would be likely to have adverse renal effects similar to those for nonselective COX inhibitors in volume-depleted horses.
authors: Schools of Animal and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW 2650, Australia.
authors: Sharanne L
authors: SL
authors: Raidal
authors: Kris J
authors: KJ
authors: Hughes
authors: Amanda-Lee
authors: AL
authors: Charman
authors: Sharon G
authors: SG
authors: Nielsen
authors: Jacqueline K
authors: JK
authors: Phillips
authors: Glenys K
authors: GK
authors: Noble
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology; D018592:Cross-Over Studies; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004232:Diuretics / Q000494:pharmacology; D004280:Dobutamine / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000494:pharmacology*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006736:Horses / Q000502:physiology*; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D008297:Male; D000077239:Meloxicam; D010653:Phenylbutazone / Q000008:administration & dosage / Q000494:pharmacology*; D010805:Physical Conditioning, Animal / Q000502:physiology; D012964:Sodium / Q000494:pharmacology; D013843:Thiazines / Q000008:administration & dosage / Q000494:pharmacology*; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002316:Cardiotonic Agents; D004232:Diuretics; D013843:Thiazines; D013844:Thiazoles; D004280:Dobutamine; D005665:Furosemide; D012964:Sodium; D051546:Cyclooxygenase 2; D010653:Phenylbutazone; D000077239:Meloxicam